{
    "clinical_study": {
        "@rank": "122811", 
        "acronym": "ReCaLL", 
        "arm_group": [
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "Experimental", 
                "description": "Standard therapy of diabetic macular edema with Lucentis (ranibizumab) according to SmPC"
            }, 
            {
                "arm_group_label": "Treatment Group", 
                "arm_group_type": "Experimental", 
                "description": "Combination of standard therapy of Lucentis (ranibizumab) according to SmPC and micropulse diode laser treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate if a combination therapy with micropulse\n      diode laser treatment shows non inferiority on visual acuity within 12 months in comparison\n      to standard therapy (intravitreal injection of ranibizumab only)."
        }, 
        "brief_title": "Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of non-ischemic diabetic macular edema with resulting reduction in visual\n             functionality by determination of best corrected visual acuity (BCVA), ophthalmologic\n             investigation, SD-OCT, FAG and anamnesis\n\n          -  BCVA between 0.05 and 0.6 or retinal thickness > 300 \u00b5m determined by SD-OCT\n\n          -  The informed consent form must be signed before any study specific tests or\n             procedures are done\n\n          -  Confirmation of the subject's health insurance coverage prior to the first screening\n             visit\n\n          -  Age at least 18 years (inclusive) at the first screening visit\n\n          -  Ability to understand and follow study-related instructions\n\n        Exclusion Criteria:\n\n          -  Severe ischemic maculopathy of the study eye\n\n          -  Active neovascularization of iris or retina in the study eye\n\n          -  History of intravitreal injection of VEGF-inhibitor or steroids in study eye within\n             the last 3 month\n\n          -  Pathologies of the anterior segment of the study eye with reduced visual acuity (e.g.\n             corneal opacification, advanced cataract)\n\n          -  Advanced glaucoma with central defects of the visual field in study eye\n\n          -  Retinal pathologies with reduced visus (e.g. central scars, age related macular\n             degeneration) in study eye\n\n          -  Retinal vascular occlusion in medical history of study eye\n\n          -  Active or suspected ocular or periocular infections\n\n          -  Active intraocular inflammation in study eye\n\n          -  Intraocular surgery of study eye within the last 6 months\n\n          -  Laser therapy of study eye within the last 6 months\n\n          -  Systemic steroid therapy within the last 3 month\n\n          -  HbA1c >10%\n\n          -  Systolic blood pressure above 170 mmHg and diastolic blood pressure above 110 mmHg\n             (after at least 3 min in supine position)\n\n          -  Pregnant or breast-feeding woman and woman without adequate method of contraception.\n\n          -  Known hypersensitivity to the active substance or to any of the excipients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059772", 
            "org_study_id": "ReCaLL-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Control Group", 
                    "Treatment Group"
                ], 
                "intervention_name": "ranibizumab", 
                "intervention_type": "Drug", 
                "other_name": "Lucentis"
            }, 
            {
                "arm_group_label": "Treatment Group", 
                "intervention_name": "micropulse diode laser", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "k.becker@skc.de", 
                "last_name": "Klio Ai Becker, MD", 
                "phone": "+49 371 33333230"
            }, 
            "facility": {
                "address": {
                    "city": "Chemnitz", 
                    "country": "Germany", 
                    "zip": "09116"
                }, 
                "name": "Klinik f\u00fcr Augenheilkunde, Klinikum Chemnitz gGmbH"
            }, 
            "investigator": {
                "last_name": "Klio Ai Becker, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study", 
        "overall_contact": {
            "email": "k.becker@skc.de", 
            "last_name": "Klio Ai Becker, MD", 
            "phone": "+49 371 33333230"
        }, 
        "overall_official": {
            "affiliation": "Klinik f\u00fcr Augenheilkunde, Klinikum Chemnitz gGmbH", 
            "last_name": "Klio Ai Becker, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "change in best corrected visual acuity (BCVA)", 
            "safety_issue": "No", 
            "time_frame": "baseline, 12 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059772"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "change in central macular thickness", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 month"
            }, 
            {
                "measure": "number of intravitreal Lucentis injections", 
                "safety_issue": "No", 
                "time_frame": "within 12 month"
            }
        ], 
        "source": "GWT-TUD GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "GWT-TUD GmbH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}